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Background: Mast cell tumors (MCTs) are the most common skin tumors in dogs and exhibit variable biologic
behavior. Mutations in the c-kit proto-oncogene are associated with the tumorigenesis of MCTs, resulting in growth
factor-independent and constitutive phosphorylation of the KIT receptor tyrosine kinase (RTK). Toceranib (TOC)
phosphate (Palladia®) is a KIT RTK inhibitor that has biological activity against MCTs. Despite these benefits, patients
ultimately develop resistance to TOC. Therefore, there is a need to identify distinguishing clinical and molecular
features of resistance in this population.
Results: The canine C2 mastocytoma cell line contains an activating mutation in c-kit. Three TOC-resistant C2
sublines (TR1, TR2, TR3) were established over seven months by growing cells in increasing concentrations of
TOC. TOC inhibited KIT phosphorylation and cell proliferation in a dose-dependent manner in the treatment-naïve,
parental C2 line (IC50 < 10 nM). In contrast, the three sublines were resistant to growth inhibition by TOC
(IC50 > 1,000 nM) and phosphorylation of the KIT receptor was less inhibited compared to the TOC-sensitive C2
cells. Interestingly, sensitivity to three structurally distinct KIT RTK inhibitors was variable among the sublines,
and all 3 sublines retained sensitivity to the cytotoxic agents vinblastine and lomustine. Sequencing of c-kit
revealed secondary mutations in the juxtamembrane and tyrosine kinase domains of the resistant sublines.
These included point mutations in TR1 (Q574R, M835T), TR2 (K724R), and TR3 (K580R, R584G, A620S). Additionally,
chronic TOC exposure resulted in c-kit mRNA and KIT protein overexpression in the TOC-resistant sublines
compared to the parental line. C2, TR1, TR2, and TR3 cells demonstrated minimal P-glycoprotein (P-gp) activity and
no functional P-gp.
Conclusions: This study demonstrates the development of an in vitro model of acquired resistance to targeted
therapy in canine MCTs harboring a c-kit-activating mutation. This model may be used to investigate the molecular
basis of and strategies to overcome TOC resistance.
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The increased understanding of molecular mechanisms
driving tumorigenesis in a wide array of neoplasms has
led to the development of novel targeted therapies.
While tyrosine kinase inhibitors (TKIs) are routinely
employed in human oncology with success, their use in
veterinary medicine is limited. Two small molecule
tyrosine kinase inhibitors, toceranib (TOC) phosphate
(Palladia®; Zoetis, Madison, NJ) and masitinib (Masivet®,
Kinavet®; AB Science, Paris, France) have been approved
by the FDA for use in veterinary medicine for the treat-
ment of recurrent, non-resectable intermediate and high
grade canine cutaneous mast cell tumors (MCTs) [1]. The
success of targeted therapies in both human and veterin-
ary oncology, however, is largely tempered by the inevit-
able development of drug resistance.
Cutaneous MCTs are the most common skin tumors
in dogs, accounting for up to 21% of all canine cutane-
ous tumors, and exhibit variable biologic behavior [2-4].
Cutaneous MCTs commonly present as a solitary mass
in older dogs with a mean age of onset of 9 years old.
There is no sex predilection. While all breeds can be
affected, Boxers, Boston terriers, Labrador retrievers,
Weimaraners, Bulldogs, Beagles, and Schnauzers are over-
represented [5].
Activating mutations in the juxtamembrane, kinase
and ligand binding domains of the c-kit proto-oncogene
have been associated with the tumorigenesis of canine
MCTs, resulting in growth factor-independent and con-
stitutive phosphorylation of the KIT receptor tyrosine
kinase (RTK). Approximately one-third of canine MCTs
carry a c-kit mutation and the majority of MCTs with
c-kit mutations are histologically intermediate or high
grade [2,6,7]. While the majority of gain-of-function mu-
tations of c-kit have been identified in exon 11 of canine
MCTs, exons 8 and 9, and less commonly exon 17, also
acquire activating mutations [8,9]. Our laboratory and
others have shown that c-kit mutations, particularly in-
ternal tandem duplications (ITD) in the juxtamembrane
domain, are significantly associated with an increased
incidence of recurrent disease, metastasis, and death
[2,6-8,10-12]. As such, small molecule inhibitors of KIT
are an attractive therapeutic strategy for MCTs in dogs.
Toceranib phosphate is one such receptor tyrosine
kinase inhibitor of KIT, approved for the treatment of
recurrent, non-resectable grades 2 and 3 canine MCTs
[13,14]. While TOC has demonstrated significant bio-
logical activity, its usefulness is significantly limited by
the eventual acquisition of drug resistance. In a multi-
center, placebo-controlled, double-blind, randomized
study of oral TOC, approximately 40% of dogs experi-
enced an objective response while the remaining 60%
demonstrated no response, likely due to de novo resist-
ance. Two-thirds of the responders were positive for anactivating mutation in c-kit. The average time to tumor
progression in all responders was 18 weeks; therefore,
virtually all dogs with MCTs have either intrinsic TOC
resistance or eventually develop resistance [13]. There-
fore, there exists a need to identify distinctive clinical and
molecular features of resistance in this population.
The aim of the current study was to develop a model
of acquired TOC resistance in canine MCT. Acquired
resistance was modeled in vitro using the TOC-sensitive
C2 canine MCT cell line to subsequently allow us to in-
vestigate mechanisms of acquired resistance in order to
ultimately develop second-line inhibitors as well as ra-
tional drug combination therapies for the treatment of
TOC-resistant MCTs in dogs.
Results
Toceranib-resistant C2 cells emerged during chronic,
stepwise TOC treatment
To explore mechanisms of acquired TOC resistance in
canine MCT, we generated three resistant sublines from
the TOC-sensitive exon 11 ITD c-kit mutant C2 cell line
designated TR1, TR2, and TR3. Growth of the parental
C2 cells was inhibited by TOC in a dose-dependent
manner with an IC50 of <10 nM. In contrast, TR1, TR2,
and TR3 sublines were resistant to inhibition by TOC
(IC50 > 1,000 nM) (Figure 1). Sensitivity to three other
KIT RTK inhibitors was similar to the observed resist-
ance to TOC. The parental line as well as all three
sublines retained sensitivity to the cytotoxic agents
vinblastine (VBL) and CCNU (Figure 2). Following 72 hr
culture in the presence of increasing concentrations of
TOC, treatment naïve, parental C2 cells detached from
the culture flask and became rounded, shrunken, and
clumped with increased exposure to TOC. In contrast,
TOC-induced morphologic differences were not identi-
fied in the resistant sublines.
Toceranib induces apoptosis in parental C2 cells, but not
the TOC-resistant sublines
Tyrosine kinase inhibitors have been shown to promote
growth inhibition in C2 cells by induction of apoptosis
and cell-cycle arrest [15]. To explore this, Terminal
Deoxynucleotidyltransferase-Mediated dUTP Nick End
Labeling (TUNEL) assays and morphological evaluations
were performed on all four cell lines to determine the ef-
fects of TOC and the cytotoxic agents, VBL and CCNU,
on apoptosis. Following 72 hr of increasing exposure to
TOC, a qualitative increase in the number of cells dis-
playing increased TUNEL reactivity and morphologic
evidence of apoptosis (chromatin condensation and nu-
clear fragmentation) was observed in the parental line. In
contrast, no increase in either positive TUNEL staining
or morphologic evidence of apoptosis was observed in
the three TOC-resistant sublines (Figure 3). The parental






























































Figure 1 Dose-dependent growth inhibition of parental line (C2) and three resistant sublines (TR1, TR2, TR3) after incubation with
increasing concentrations of toceranib phosphate or three other KIT receptor tyrosine kinase inhibitors (LY2457546, masitinib,
imatinib) for 72 hours.
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equivalent increase in both TUNEL staining and apop-
totic morphology after 72 hr of VBL (Figure 4) or CCNU
exposure (data not shown).
KIT phosphorylation in resistant cells does not decrease
after toceranib treatment
To determine whether the lack of growth inhibition ob-
served in the resistant sublines in Figure 1A was due
to a lack of inhibition of autophosphorylation by TOC,
the cells were incubated with increasing concentrations
of TOC for 24 hours and western analysis for phosphor-
ylated and total KIT was performed. TOC inhibited
KIT phosphorylation in the parental C2 line in a dose-














Figure 2 Dose-dependent growth inhibition of parental line (C2) and
increasing concentrations of vinblastine or CCNU (lomustine) for 72 hreceptor was maintained in the presence of TOC in all
three resistant sublines (Figure 5).
Chronic TOC exposure resulted in significant
overexpression of c-kit mRNA and KIT protein in the TOC-
resistant sublines
To investigate whether overexpression of the target kin-
ase contributes to the observed TOC resistance, c-kit
mRNA and KIT protein expression was measured by
real-time quantitative PCR and flow cytometry, respect-
ively. Indeed, TOC-resistant sublines demonstrated up
to a four-fold increase in KIT receptor expression com-
pared to the parental, treatment naïve C2 cells (Figure 6A
and B). Additionally, densitometric analysis of chemilumin-














three resistant sublines (TR1, TR2, TR3) after incubation with
ours.





Figure 3 Effect of toceranib and vinblastine (B) on the induction
of apoptosis in C2, TR1, TR2, and TR3 cells; Red- TUNEL;
DAPI counterstain.
Figure 5 Western blot analysis of KIT activation (phosphorylated
KIT) in parental line (C2) and three resistant sublines (TR1, TR2,
TR3) after incubation with increasing concentrations of toceranib
phosphate for 24 hours.
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Bethesda, MD), which demonstrated significant over-
expression of KIT in all three resistant sublines com-
pared to the parental line (data not shown).
C2, TR1, TR2, and TR3 sublines demonstrate minimal P-gp
activity and no functional P-gp
To determine if TOC resistance is caused by overex-
pression and increased functional activity of the drug
transporter P-glycoprotein (P-gp), western analysis and
rhodamine uptake/efflux assays were performed, respect-
ively, in all four sublines. While MDR1-overexpressing
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Figure 4 Effect of vinblastine on the induction of apoptosis in
C2, TR1, TR2, and TR3 cells; Red- TUNEL; DAPI counterstain.all four sublines demonstrated little to no P-gp expres-
sion, even when blots were overexposed (Figure 7A). Fur-
thermore, densitometric analysis of chemiluminescent
signals of P-gp showed no significant differences in P-gp
expression in the resistant sublines versus the parental
line (data not shown). The activity of P-gp in the same
cells was determined by rhodamine uptake/efflux. As ex-
pected, MDR1-MDCK cells demonstrated a lower fluor-
escence signal compared to C2, TR1, TR2, and TR3
cells. Administration of the P-gp inhibitor, verapamil, in-
creased the fluorescence signal in the MDR1-MDCK
cells, however, no shift in the fluorescence signal was de-
tected in the C2, TR1, TR2, and TR3 cells (Figure 7B).
Secondary c-kit mutations are present in the juxtamem-
brane and kinase domains of c-kit in resistant sublines
To assess whether the development of secondary muta-
tions in the c-kit gene conferred the observed resistance
to TOC, full-length canine c-kit from the TOC-sensitive
and -resistant sublines was cloned and sequenced. cDNA
sequence analyses of full length c-kit from each clone
after assembly and comparison of 7-10 clones from each
subline was performed. A total of six point mutations
were identified in the juxtamembrane and kinase do-
mains of 30-50% of the resistant clones. These included
Q574R in exon 11 and M835T in exon 18 of TR1;
K724R in exon 15 of TR2; and K58R in exon 11, R584G
in exon 11, and A620S in exon 12 of TR3 (Figure 8).
These novel mutations were not identified in any of the
parental C2 clones. Additionally, alternative splice sites
between exons 9 and 10 and exons 17 and 18 were iden-
tified in all sublines. These transcripts utilize alternate
splice donors (GT) 3′ to exons 9 and 17. Furthermore,
retention of the original 48-bp internal tandem duplica-
tion in exon 11 of the parental line was observed in all
three resistant sublines.
Discussion
The identification of protein kinases as instrumental
regulators in the tumorigenesis of many forms of neo-
plasia has led to the development of numerous small
molecule kinase inhibitors for the treatment of cancer.













































































Figure 6 Analysis of c-kit and KIT expression in C2, TR1, TR2, and TR3 cells by RT-qPCR (A) and flow cytometry (B), respectively.
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MCT, its addiction to a dominant oncogene, coupled
with the identification of a “druggable” target has re-
sulted in significant progress toward its treatment. Ac-
tivating mutations in the c-kit proto-oncogene confer
growth-factor independent activation of the KIT recep-
tor tyrosine kinase, subsequent downstream signaling,
and enhanced proliferation and survival of malignant
mast cells [4,16]. Ligand-independent activation of the
KIT pathway most commonly occurs due to a muta-
tion in the juxtamembrane domain in exon 11 [6].A
B
Figure 7 Expression and function of P-gp in C2, TR1, TR2, and
TR3 cells (A) Western blot analysis of P-gp expression in at 240
and 1060 second exposures and (B) Rhodamine efflux/uptake
assay in the same cells as A. Administration of the P-gp inhibitor,
verapamil, increases fluorescence signal in lines with functional P-gp
(MDCK-MDR1) with relatively no change in signal in lines without
functional P-gp (C2, TR1, TR2, TR3).This domain has a negative regulatory function by
maintaining the KIT receptor in its inactive conform-
ation in the absence of ligand binding. Mutations in
this domain result in an active conformation due to
disruption of the inhibitory motif resulting in auto-
phosphorylation of the KIT receptor and downstream
signaling [17]. Upon binding the ATP-binding pocket
within the TK domain, the small molecule KIT recep-
tor tyrosine kinase inhibitors abrogate KIT signaling
and induce growth inhibition and apoptosis [14,18].
Dogs with MCTs harboring an activating mutation in
the c-kit proto-oncogene have demonstrated signifi-
cantly increased response rates to TOC [13]. Despite
these benefits, the responses are often transitory as tu-
mors commonly develop resistance to TOC.
To begin to identify mechanisms of acquired resist-
ance to TOC, we have successfully developed a model of
acquired resistance using a canine MCT cell line by con-
tinuously exposing cells to increasing concentrations of
TOC, resulting in three independent sublines that are
resistant to TOC. The C2 MCT cell line harbors the
KIT-activating ITD mutation in exon 11, which repre-
sents the most common mutation in canine MCT [8,10].
In one study, 64% of KIT mutations identified in canine
MCT were ITDs in exon 11 [8]. As such, the C2 cell line
is a clinically-relevant canine MCT line for these investi-
gations. While the parental C2 line demonstrated dose-
dependent growth inhibition following treatment with
TOC, the three sublines, TR1, TR2, and TR3, remained
resistant to TOC exposure. Similarly, TOC exposure
caused an induction of apoptosis in the parental line
while no evidence of apoptosis was observed in the three
sublines following similar TOC exposure. Importantly,
the TOC-resistant sublines retained sensitivity to the
cytotoxic agents vinblastine and CCNU, and demon-
strated variable sensitivity to other KIT kinase inhibitors.
This lack of apparent cross-resistance to the conventional
AB
C
Figure 8 Point mutations identified in 7-10 clones of full-length c-kit from (A) TR1, (B) TR2, and (C) TR3 sublines. Mutations were
commonly identified in functional domains of the KIT receptor.
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may remain active in patients with TOC-refractory disease.
In dogs, the range of achievable concentrations for TOC
in vivo has been reported between 30 nM (Cmin) and
200 nM (Cmax) [19,20]. In the current study, growth in-
hibition assays were carried out to 1 uM, nearly 5-fold the
reported Cmax for TOC. However, there may be a small
therapeutic window in which higher concentrations of
masitinib may override TOC-resistance in MCT as the
tested concentrations were lower than the Cmax reported
in dogs (1.3 uM-1.5 uM) but, this is beyond the scope of
the current investigations [21].
There are several reported pathway-dependent mecha-
nisms of acquired resistance to tyrosine kinase inhibitors.
One of the most common mechanisms is acquisition of
secondary mutations within the target oncogene leading
to either reactivation of the target protein or induc-
tion of a conformational change in the drug binding
pocket resulting in reduced binding affinity [22-26].
As KIT tyrosine kinase inhibitors bind to the ATP-
binding pocket of a kinase in a competitive fashion,
mutations located in the in the drug/ATP-binding pocket
of the receptor are associated with acquired drug resist-
ance. Heinrich and co-workers showed that secondary
point mutations located in the ATP-binding pocket of the
KIT receptor (encoded by exons 13 and 14) are associated
with resistance to imatinib, a KIT receptor tyrosine kinase
inhibitor, in gastrointestinal stromal tumors (GISTs) [27].
In the current study, the observed variable resistance
to the three other KIT inhibitors, both between thethree inhibitors (imatinib, masitinib and LY2457546)
and among the three resistant sublines, suggests that
there may be differences in drug binding kinetics among
the four compounds and perhaps differences in mecha-
nisms of acquired resistance between the three sublines,
respectively.
Engagement of alternative or bypass signaling path-
ways is another common mechanism of acquired resist-
ance to receptor tyrosine kinase inhibitors [28-31]. This
can occur independent of the target oncogene to which
a tumor is addicted. Indeed, the activation of a bypass
pathway has been shown to overcome KIT inhibition in
human GISTs. GIST cells resistant to imatinib demon-
strated increased activation of the AKT pathway leading
to continued cell growth and survival [32,33]. Nazarian
and co-workers showed that melanomas harboring a
BRAF (V600E) mutation eventually become resistant to
the RAF-selective inhibitor, PLX4032, by activation of an
alternative survival pathway mediated by PDGFRβ [34].
In addition to secondary mutations in the target onco-
gene and activation of bypass signaling pathways, resist-
ance to targeted therapies can also occur through
activation of effector proteins upstream and/or down-
stream of the intended target. Nazarian and co-workers
also demonstrated reactivation of NRAS signaling in
PLX4032-refractory melanomas leading to MAPK pathway
reactivation and disease progression [34]. Similarly, Wagle
and co-workers demonstrated activating mutations in
MEK1 and subsequent reactivation of the MAPK pathway
following treatment of melanoma with PLX40 [35].
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resistant canine MCT model, we examined KIT acti-
vation status in the parental and TOC-resistant C2
sublines by western blot analysis using an antibody
against KIT phosphorylated at Tyr719. While phos-
phorylated KIT was reduced in a dose-dependent manner
in the parental line, KIT activation was maintained in the
presence of increasing concentrations of TOC in all three
resistant sublines. These data led to the hypothesis that
acquisition of a secondary mutation in the c-kit proto-
oncogene would be, in part, responsible for the observed
TOC resistance. To that end, full-length canine c-kit was
cloned and sequenced. The original ITD mutation in
exon 11 was maintained in all three resistant sublines. In-
deed, we detected several different point mutations in the
resistant sublines leading to amino acid substitutions.
Interestingly, all of these mutations were located in the
functional domains of the KIT receptor. Computational
modeling of these mutations is in process to ascertain
whether they impede contact between the KIT inhibitors,
including TOC, and their binding sites or alter spatial
conformation of the target protein. The frequency with
which these mutations were identified in the resistant
clones was between 30-50%. This likely represents the
heterogeneity associated with resistance mechanisms. It
has been shown that multiple drug-resistant mutations
and disparate mechanisms of resistance can frequently
occur in a single population of tumor cells [30,36-38].
These include from multiple secondary mutations in the
target kinase as well as independent mechanisms such as
activation of a bypass pathway. Other single nucleotide
polymorphisms (SNPs) were identified in single clones.
These are likely a result of polymerase error when ob-
served in a single clone, but when duplicated represent
transcript heterogeneity resulting from genomic instabil-
ity perhaps as a result of deficiencies in the DNA repair
machinery. Alternative signaling pathways that bypass in-
hibition of the target protein, KIT, were not pursued in
the current study. Constitutive activation of KIT in the
presence of TOC in the resistant sublines strongly sug-
gests that the mechanism of resistance occurs at the level
of the KIT receptor.
A final pathway-dependent mechanism of acquired
resistance is through genomic amplification of the tar-
get gene. Amplification of the target gene and subse-
quent overexpression of the target kinase, can alter the
drug-target stoichiometry such that inhibition is dimin-
ished and cell survival and proliferation persists [39-43].
Genomic amplification of c-kit has been reported in
imatinib-resistant GISTs as a mechanism of acquired re-
sistance [44]. Ercan and co-workers demonstrated that
although non-small lung cancers harboring a EGFR
T790M mutation transiently respond to EGFR inhibitors,
clones over-expressing EGFR T790M eventually emergeleading to clinical resistance [41]. Increased expression of
the target protein BCR/ABL, resulting from genomic
oncogene amplification, was observed in chronic myelog-
enous leukemia (CML) cell lines that became refractory
to the selective ABL tyrosine kinase inhibitor imatinib
[40]. In the current study, analysis of c-kit mRNA expres-
sion by real-time quantitative PCR demonstrated a sig-
nificant increase in c-kit expression in the TOC-resistant
C2 sublines compared to the treatment-naïve parental C2
cells. To determine if this increase in c-kit transcript led
to a subsequent increase in KIT receptor expression, flow
cytometry was performed. Indeed, a significant increase
in KIT receptor expression was demonstrated in the
three TOC-resistant C2 sublines compared to the TOC-
sensitive parental C2 cells. This could confer the ob-
served resistance as binding of TOC to the overexpressed
target could deplete the amount of intracellular drug
available. As such, increasing the dose of TOC would be
a reasonable therapeutic approach to overcome KIT-
overpexpressing TOC-resistant canine mast cell tumors.
However, in the current model, growth inhibition assays
were carried out to doses of TOC 100-fold the IC50 of
the treatment naïve parental C2 cells and an IC50 was not
reached in all three resistant lines. Therefore, these data
suggest that a four-fold increase in expression of the tar-
get protein by itself is likely not adequate to confer the
observed resistance. Amplification of the target onco-
gene, and subsequent overexpression of the encoded
target protein, may have been driven in response to
continued pressure by the KIT inhibitor. Alternatively,
because the TOC-resistant sublines initially responded to
TOC and maintained the original ITD activating c-kit
mutation in exon 11, it is possible that the resistant sub-
lines were derived from a distinct c-kit-amplified subpop-
ulation of c-kit-mutant cells that were subsequently
selected for during TOC administration.
While the current study focuses on pathway-dependent
mechanisms of KIT RTK resistance, there are several re-
ported pathway-independent mechanisms of resistance
that were investigated. These include pharmacological fac-
tors that ultimately diminish drug exposure. Drug-efflux
pumps, such as P-glycoprotein (P-gp) encoded by MDR1,
have been shown to be overexpressed in several TKI-
resistant tumors and cell lines. Mahone and co-workers
reported a significant overexpression of P-gp in imatinib-
resistant leukemia cell lines [45]. Furthermore, sensitivity
was restored following administration of several P-gp in-
hibitors. Nakaichi and co-workers reported the expression
of P-gp and MDR-1 by western blot analysis and RT-PCR,
respectively, in several canine MCT cell lines, excluding
C2 [46]. Sunitinib, a structural analog of toceranib, has
been shown to be a substrate of P-gp. As such, we investi-
gated the role of drug efflux in TOC-resistant canine C2
cells as a mechanism of resistance by measuring P-gp
Halsey et al. BMC Veterinary Research 2014, 10:105 Page 8 of 12
http://www.biomedcentral.com/1746-6148/10/105expression and function [47]. The expression of P-gp
was determined in all four C2 sublines and MDR1-
overexpressing MDCK cells by western analysis. While the
presence of P-gp was confirmed in all four sublines, there
were no significant differences in expression between the
TOC-sensitive cells and TOC-resistant cells. Furthermore,
all four C2 sublines showed minimal functional P-gp as
measured by rhodamine efflux with or without administra-
tion of the P-gp inhibitor, verapamil.
Conclusions
Sustained KIT signaling appears required for c-kit mutant
MCT survival. Regardless of the specific mechanism of ac-
quired TOC resistance outlined above, all may lead to re-
activation of the KIT signaling pathway and ultimately
tumor progression. Our results demonstrate that continu-
ous, chronic exposure of C2 cells to TOC causes eventual
drug resistance. We demonstrate that overexpression of
the KIT receptor is, in part, responsible for the observed
TOC resistance, and have identified several candidate mu-
tations that may play a role in resistance acquisition. The
identification of these and other potential mechanisms of
TOC resistance is necessary for the identification of second
line KIT inhibitors or alternate therapeutic strategies for
the treatment of high grade, non-resectable canine MCT
that are refractory to TOC. Furthermore, we have created
in vitro tools that can be utilized for future study of re-
sensitization strategies for TOC-resistant canine MCT.
Methods
Cell culture and generation of toceranib-resistant sublines
from C2 cells
Toceranib phosphate was provided by Zoetis (Florham
Park, NJ). Masitinib (AB1010, Kinavet®) and LY2457546
were provided by AB Science (Paris, France) and Elanco
(Greenfield, IN), respectively. Imatinib was purchased from
Selleck Chemical (Houston, TX). Vinblastine (VBL) and
lomustine (CCNU) were purchased from Sigma (St. Louis,
MO). Stock solutions of all drugs were prepared in DMSO
and stored at -20°C. The c-kit mutant canine C2 mastocy-
toma cell line, derived from a spontaneously occurring
cutaneous MCT, was used as the parental cell line [48].
Cells were propagated in RPMI 1640 supplemented with
2 mM L-glutamine, 10% FBS, 100 g/mL streptomycin, and
100 U/mL penicillin in a 37°C incubator under a humidi-
fied atmosphere of 5% CO2. TOC-resistant C2 cells were
selected by growing C2 cells in concentrations of TOC
ranging from 0.02 uM to 0.3 uM and increasing in 0.025-
0.05 uM increments. Three independent, TOC-resistant
sublines were established over a period of 7 months.
Drug sensitivity assays
The sensitivity and resistance of each cell line to TOC,
three other kinase inhibitors, and the cytotoxic agentsVBL or CCNU were determined by measuring relative
viable cell number using a fluorometric bioreductive
assay (Alamar Blue, Promega; Madison, WI). All three
C2 sublines as well as the treatment naïve, parental C2
cells were plated in triplicate in 96-well plates at dens-
ities of 2,000 cells per well. Cells were treated with in-
creasing concentrations of TOC, three other KIT kinase
inhibitors, VBL or CCNU for 72 hours. Alamar Blue re-
agent was added to all wells, plates were incubated
for 1 hour at 37°C, and fluorescence was measured on a
BioTek plate reader (BioTek, Winooski, VT). Dose-
response curves were generated using Prism (GraphPad
Software, La Jolla, CA).
Terminal Deoxynucleotidyltransferase-Mediated dUTP
Nick End Labeling (TUNEL) apoptosis assays
To evaluate drug effects on the induction of apoptosis,
the C2 parental and three TOC-resistant sublines were
treated for 24 hr with increasing concentrations of TOC
(0-100 nM) and the cytotoxic agents VBL and CCNU
(0 ug/mL-100 ug/mL). Cells were harvested and resus-
pended in media. Approximately 250,000 cells were
centrifuged at 40 x g for 4 minutes onto glass slides.
Cytospins were dried and stored at 4°C overnight fol-
lowed by fixation in 4% paraformaldehyde for 60 min at
room temperature. Cells were permeabilized with 0.1%
Triton X-100 in 0.1% sodium citrate solution for 2 min
on ice. TUNEL staining was carried out following the
manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN). Slides were counterstained and mounted
with DAPI (Vector, Burlingame, CA). Image analysis was
performed using AxioVision 4.3 system software from Carl
Zeiss using an Axioplan 2 imaging scope coupled with an
AxioCam HRc Carl Zeiss camera.
Western blot analysis
To evaluate drug effects on KIT autophosphorylation,
parental C2 cells and the resistant sublines were incu-
bated for 24 hours with increasing concentrations of
TOC (0-100 nM) and phosphorylated and total KIT were
analyzed by western blot. Cells were resuspended in lysis
buffer containing 1% Triton X-100, 100 nM sodium
orthovanadate, 0.2 mM PMSF, 1 M Tris, 1 M NaCl, and
7X protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN), incubated on ice for 15 min, and
centrifuged for 5 min. Protein was separated by SDS-
PAGE on a 6% acrylamide gel and transferred onto a
polyvinylidene difluoride membrane. Membranes were
blocked for 60 min at room temperature in 5% bovine
serum albumin. Immunolabeling for KIT was performed
using a rabbit polyclonal anti-human antibody (Dako,
Carpinteria, CA) at 1:1000 while immunolabeling for
pKIT was performed using a rabbit polyclonal anti-human
antibody (Cell Signaling Technology, Beverly, MA) at






FOR1 501–1000 448 GACGGACCCAGAAGTGACC
FOR2 1001–1500 948 CCTTGGAAGTAGTAGATAAAGGATTCA
FOR3 1501–2000 1453 AGTGGTTCAGAGTTCCATCG
FOR4 2001–2500 1948 CAAAGTCTTGAGTTACCTCGG
FOR5 2501–3000 2950 TGTGTGAAGCAGGAGGAGTG
REV1 500–1 552 CTGATCGTGATGCCAGCTT
REV2 1000–501 1040 CAATCAGATCCACATTCTGTCC
REV3 1500–1001 1542 GCAGAACTCCTGCCTACATTG
REV4 2000–1501 2040 TATTCTGTAATGACCAAGGTGGG
REV5 2500–2001 2552 TGAAAATGCTCTCAGGGGC
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with HRP-conjugated anti-rabbit antibody at 1:5000
for 30 min at room temperature. Immunoreactive bands
were detected using enhanced chemiluminescent reagents
(Thermo Scientific, Rockford, IL).
Mutational analysis: cloning and sequencing of c-kit
Full-length canine c-kit from the TOC-sensitive
and -resistant sublines was cloned and sequenced. Total
RNA was extracted from C2 cells using RNeasy Mini-kit
after homogenization using QIA-shredder columns ac-
cording to the manufacturers instructions (Qiagen;
Valencia, CA). First strand cDNA was synthesized using
ThermoScript™ RT-PCR System (Invitrogen; Carlsbad,
CA) according to the manufacturers instructions. Full-
length canine c-kit was amplified using Platinum® Taq
DNA polymerase High Fidelity (Invitrogen) and the fol-
lowing primers: c-kit Forward AGGCTATCGCAGCFigure 9 Sequencing strategy of full-length canine c-kit with forwardCACCGCGATGAG and c-kit Reverse GATCGCTCTT
GTTGGGGAGAC. The conditions for PCR amplifica-
tion were as follows: pre-denaturation at 94°C for 2 min,
40 cycles of denaturation at 94°C for 30 sec, annealing at
57°C for 30 sec, extension at 68°C for 3 min 30 sec and,
following the final cycle, an additional extension at 68°C
for 7 min was performed. The PCR products were puri-
fied according to the QIAquick PCR purification kit
instructions. The concentration was determined using
a Nanodrop 1000 spectrophotometer (Thermoscientific;
Wilmington, DE). The cDNA fragment of interest was li-
gated into a pGEM®-T easy vector (Promega) by T4 ligase
at 4°C overnight. The product was transfected to compe-
tent DH5α bacteria. Positive recombinants were selected
on a Luria-Bertani (LB) plate with X-gal and 100 μg/mL
ampicillin. The white bacterial colonies were selected,
amplified and plasmids were extracted and purified using
the QIAquick DNA reagent kit (Qiagen). Positive clones
were selected by restriction endonuclease digestion with
EcoRI and SpeI restriction enzymes and positive recom-
binants were sequenced. Sequencing was performed
using the dideoxynucleotide chain termination method
(Sanger Method) with an automatic sequencer (ABI
3130xL Genetic Analyzer) using T7 and SP6 promoter
primers and five internal sequencing primers (Table 1,
Figure 9). Assembly, editing and comparison of all cDNA
sequences was performed using Geneious Pro version 5.5.8
created by Biomatters (http://www.geneious.com/). Briefly,
multiple clones from each cell line were compared to elim-
inate potential polymerase errors. For each clone, full-
length c-kit sequence was assembled from a series of over-
lapping sequence reads. Contig assembly and multiple se-
quence alignments were performed using the “Assembly”
and “Alignment” functions of Geneious, respectively.and reverse internal sequencing primers.
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Real time-quantitative PCR (RT-qPCR)
To evaluate the effects of chronic TOC exposure on
mRNA expression of c-kit, RT-qPCR was performed on
both TOC-sensitive and –resistant C2 cells. RNA was
extracted, purified, and cDNA synthesis performed as
described above. RT-qPCR was performed on five bio-
logical replicates in triplicate with denaturation at 94°C
for 2 minutes and 40 cycles of 30 seconds at 94°C
(melting) and 60 seconds at 57°C and 3 minutes and
30 seconds at 68°C (annealing and elongation) followed
by 7 minutes at 68°C using the iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA) and 25 ng equivalent RNA
input in 25 μL reactions on a Stratagene Mx3000P
thermal cycler (Stratagene; La Jolla, CA). Primers were
designed to be intron-spanning using Geneious. The
standard curves, dissociation curves, and amplification
data were collected using Mx3000P software and ana-
lyzed with the 2(-ΔΔCt) method [49]. In all cases, the amp-
lification efficiencies were greater than 90% and both
amplicon size and sequence were confirmed. Expression
levels were normalized to hypoxanthine phosphoribosyl-
transferase 1 (HPRT1) expression. HPRT was selected as
a reference gene since it did not exhibit significant vari-
ation among our experimental samples. The c-kit forward
primer sequence was 5′- TTGGTCTAGCCAGAGACA
TCAA -3′, the c-kit reverse primer sequence was 5′
TGAAAATGCTCTCAGGGGC -3′, the HPRT1 forward
primer sequence was 5′-TGC TCG AGA TGT GAT
CAA GG-3′ and the HPRT1 reverse primer sequence
was 5′-TCC CCT GTT GAC TGG TCA TT-3′.
Flow cytometry
To evaluate the effects of chronic TOC exposure on KIT
expression, flow cytometric analysis was performed on
three biological replicates of TOC-sensitive and –resistant
lines in triplicate. 250,000 parental C2 and TR1, TR2, and
TR3 cells were incubated with 0.4ug PE-conjugated rat
anti-mouse monoclonal CD117 (BD Pharmingen; San Jose,
CA) for 30 minutes in the dark at room temperature,
washed with 1X PBS, centrifuged at 200 x g for 5 minutes,
and resuspended in 1X PBS. Data was acquired using a
Gallios flow cytometer and Gallios software (Beckman
Coulter; Brea, CA). Results were analyzed using Kaluza
Analysis Software (Beckman Coulter). Cells were gated
based on forward scatter and side scatter properties.
P-gp expression/function
To evaluate the expression and function of P-gp in the
TOC-sensitive and -resistant sublines, western blotting
and rhodamine uptake/efflux was performed, respectively.
C2, TR1, TR2, and TR3 cells were lysed as described
above. As a positive control, MDR1-over-expressing
canine Madin Darby Canine Kidney (MDCK) cells wereused (kindly received from Dr. Michael Gottesmann,
Laboratory of Cell Biology, National Cancer Institute,
NIH, Bethesda, MD). Protein was separated by SDS-PAGE
on a 6% acrylamide gel and transferred onto a polyvinyli-
dene difluoride membrane. Membranes were blocked for
60 min at room temperature in 4% milk. Immunola-
beling for MDR-1/Pg-p/ABCB1 was performed using a
rabbit polyclonal anti-human antibody (Novus Biologicals,
Littleton, CO) at 1:1000 followed by incubation with HRP-
conjugated anti-rabbit antibody at 1:5000 for 30 min at
room temperature. Immunoreactive bands were detected
using enhanced chemiluminescent reagents (Thermo
Scientific; Rockford, IL). Rhodamine uptake/efflux as-
says were performed as previously described [50,51].
Briefly, 200,000 cells were seeded in 6-well plates 24 hr
prior to assay. Cells were incubated in rhodamine (3 μM)
or rhodamine and verapamil (50 μg/mL) for 1 hr at 37°C.
Rhodamine-containing media was removed, replaced with
fresh media or media and verapamil, and placed at 37°C
for 1 hr. Cells were harvested, washed, and flow cytometry
was performed to measure fluorescence intensity.Ethical statement
This study does not need approval from an ethical
committee.
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